不过,他仍然乐观地认为,疫苗将在有史以来非常短的时间内研发出来。他提到了一种很有希望的备选疫苗,认为可能在夏初进入临床试验。福奇表示,他认为最终的疫苗最早可于明年1月大量投入使用,这将打破以往疫苗研发速度的纪录。
One reason for his confidence is the “impressive” results being seen now in animals tested with a vaccine candidate made by Cambridge, Massachusetts-based Moderna Therapeutics, which brought it into human trials in a record 42 days. The candidate is what is known as an mRNA vaccine—a drug that uses snippets of a virus’s genetic material—rather than the dead or weakened virus itself—to build the proteins that trigger the body’s protective immune response.
他有信心的一个原因是,马萨诸塞州剑桥市Moderna Therapeutics公司生产的一种备选疫苗进行的动物试验结果“引人瞩目”,使其创纪录地在42天内进入人体试验阶段。这种疫苗被称为mRNA疫苗,是一种利用病毒遗传物质的片段而不是死亡或被削弱的病毒本身来制造蛋白质,从而触发人体保护性免疫反应的疫苗。
snippet[ˈsnɪpɪt]:n.小片;片断
To date, no type of mRNA vaccine has been licensed for use in humans, but Fauci believes there is great promise for this technology targeting the coronavirus, based in part on his experience developing treatments for HIV/AIDS in the 1980s and ‘90s.
【福奇:没有科学证据表明新冠病毒来自中国实验室】相关文章:
★ 从现在开始行动吧
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15